Retatrutide vs. Tirzepatide: A Comprehensive Comparison

‍

In the ever-evolving landscape of weight loss management, innovative medications known as glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide (brand names Ozempic and Wegovy) and tirzepatide (brand names Mounjaro and Zepbound), have emerged as promising treatments for individuals who are overweight or obese (1,2). Worldwide, type 2 diabetes affects more than 500 million people, and obesity affects over 890 million (3,4). Given the prevalence of these chronic conditions, scientists are working to develop more effective treatments. Currently in development is a new medication called retatrutide, which has shown promising results in the early stages. Delving into the nuances of these medications is vital for healthcare professionals and patients alike to make informed decisions regarding their diabetes care. This article sheds light on the difference between the well-known tirzepatide and the newer, up-and-coming medication retatrutride.

Differences Between Retatrutride and Tirzepatide

Tirzepatide and retatrutide have garnered significant attention for their ability to aid in weight loss. Here we look into the differences between tirzepatide and retatrutride, including what’s currently on the market, how these medications work, and how effective they are at helping individuals lose weight.

How Long Has Tirzepatide Been Around Vs. Retatrutride? 

Tirzepatide was first approved for diabetes treatment in 2022 under the brand name Mounjaro after initial studies demonstrated its effectiveness in lowering blood sugar (5). Soon after, it was discovered that the medication was also very beneficial for weight loss in individuals without type 2 diabetes (2). In 2023, the U.S. Food and Drug Administration (FDA) approved the brand label Zepbound, which is a tirzepatide injection for weight loss in adults with obesity or overweight with a weight-related condition (i.e., type 2 diabetes, high blood pressure) as an adjunct to a reduced calorie, healthy diet and daily physical activity (6).

On the other hand, retatrutide is still in clinical trials and not yet on the market. Though still relatively new, scientists are excited about the prospects of retatrutride as it’s thus far shown remarkable effectiveness in treating obesity (7). In rodent studies, retatrutride has been shown to induce greater weight loss in obese mice compared to tirzepatide (8). In a small, early-stage trial, a standard dose of retatrutride resulted in an average weight loss in human adults of approximately 18% at 24 weeks and 24% at 48 weeks (9). In another small, early-stage trial, retatrutride demonstrated significant improvements in blood sugar (10). These findings underscore the potential of retatrutide as a viable alternative to medications such as semaglutide and tirzepatide.

Tirzepatide vs. Retatrutride: How Do They Both Work?

Tirzepatide operates as a dual agonist for GLP-1 and GIP (Glucose-Dependent Insulinotropic Polypeptide) receptors, meaning it mimics and enhances a naturally occurring mechanism in our body. The medication regulates blood sugar levels, suppresses appetite, and increases feelings of satiety. It helps patients feel fuller for longer, even when eating less food (2, 11).

Retatrutride goes a step further. In addition to acting as an agonist for GLP-1 and GIP receptors, it also targets the glucagon (GCG) receptor (7). As a triple agonist targeting GLP-1, GIP, and GCG receptors, retatrutride represents an advanced approach to managing type 2 diabetes and obesity.  

How To Choose Between Retatrutide vs. Tirzepatide

Tirzepatide is an FDA-approved medication for weight loss. Although retatrutride is currently unavailable, its novel approach shows promise in enhancing weight reduction outcomes in the future. As larger-scale studies surface in the near future, retatrutride is a medication worth keeping an eye on. 

In conclusion, retatrutride and tirzepatide represent significant advancements in obesity therapeutics, each presenting distinct attributes and considerations for patients and healthcare providers, especially in the future if retatrutride hits the market. 

‍

Find The Right Weight Care Plan With Mochi Health

Navigating many treatment options and nuances within weight management care can be daunting. Mochi Health offers comprehensive guidance and resources to empower individuals to make well-informed decisions about their health. Mochi Health’s weight care program offers access to personalized treatment strategies, expert advice, and holistic care plans tailored to their unique needs. See if you’re eligible to join Mochi Health today. 

Sources:

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., Kushner, R. F., & STEP 1 Study Group (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine, 384(11), 989–1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
2. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
3. 3. Ong, K. L. et al. Lancet 402, 203–234 (2023). https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01301-6/fulltext
4. 4. WHO. https://www.who.int/news-room/fact-sheets/detail/obesityand-overweight (2024).
5. Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K; SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021 Aug 5;385(6):503-515. doi: 10.1056/NEJMoa2107519. Epub 2021 Jun 25. PMID: 34170647. https://www.nejm.org/doi/full/10.1056/NEJMoa2107519
6. Abbasi J. FDA Green-Lights Tirzepatide, Marketed as Zepbound, for Chronic Weight Management. JAMA.2023;330(22):2143–2144. doi:10.1001/jama.2023.24539
7. Li, W., Zhou, Q., Cong, Z. et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discov 10, 77 (2024). https://doi.org/10.1038/s41421-024-00700-0
8. Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, O'Farrell LS, Briere DA, Sloop KW, Thomas MK, Pirro V, Wainscott DB, Willard FS, Abernathy M, Morford L, Du Y, Benson C, Gimeno RE, Haupt A, Milicevic Z. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022 Sep 6;34(9):1234-1247.e9. doi: 10.1016/j.cmet.2022.07.013. Epub 2022 Aug 18. PMID: 35985340. https://www.cell.com/cell-metabolism/fulltext/S1550-4131(22)00312-6?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1550413122003126%3Fshowall%3Dtrue
9. Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML; Retatrutide Phase 2 Obesity Trial Investigators. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023 Aug 10;389(6):514-526. doi: 10.1056/NEJMoa2301972. Epub 2023 Jun 26. PMID: 37366315. https://www.nejm.org/doi/10.1056/NEJMoa2301972
10. Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023 Aug 12;402(10401):529-544. doi: 10.1016/S0140-6736(23)01053-X. Epub 2023 Jun 26. PMID: 37385280. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01053-X/abstract‍
11. MOUNJARO(Tirzepatide) Injection, for Subcutaneous Use.” Access Data FDA, Food and Drug Administration, www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf